Thermo Fisher Scientific (NYSE: TMO) reported Q4 EPS of $2.41, $0.03 better than the analyst estimate of $2.38. Revenue for the quarter came in at $4.95 billion versus the consensus estimate of $4.98 billion.

"I’m pleased to report that we achieved the goals we laid out for 2016, and successfully executed our strategy to deliver another excellent year,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific.

“We effectively deployed the largest R&D budget in our industry, and launched new high-impact products across all of our technology platforms. In Asia-Pacific and emerging markets, we leveraged our industry-leading scale to drive strong growth, especially in China, where we’re capturing opportunities aligned with the new five-year plan.

“We also continued to successfully execute our capital deployment strategy to create value for our shareholders. I’m really excited about our acquisition of FEI – the third largest in our history – and look forward to the opportunities we have to leverage these complementary technologies to drive growth.

“To sum it up, with a strong 2016 behind us, we’re positioned for another great year ahead.

For earnings history and earnings-related data on Thermo Fisher Scientific (TMO) click here.